Bulk Inquiry
Doxercalciferol
- Hectorol - TSA 840- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C28H44O2
- MW: 412.65
Description
Doxercalciferol is a vitamin D2 analogue with vitamin D receptor (VDR) agonist activity.
VDR activation regulates calcium and phosphate homeostasis, parathyroid hormone biology and transcriptional programs linked to differentiation and mineral metabolism. Doxercalciferol is useful as a vitamin D receptor pharmacology reference compound.
Key Features
- Vitamin D2 analogue with VDR agonist activity
- Activates vitamin D receptor-dependent transcription
- Relevant to calcium and phosphate homeostasis pathways
- Clinically relevant mineral metabolism pharmacology
Applications
- VDR nuclear receptor assays
- Calcium and phosphate metabolism research
- Parathyroid hormone pathway studies
- Vitamin D analog pharmacology
More Information
| Parent CAS No. | 54573-75-0 |
|---|---|
| Chemical Name | (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol |
| SMILES | [C@]12(C)CCC/C(=CC=C3C[C@H](C[C@H](O)C3=C)O)/[C@]1([H])CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C |&1:0,10,12,17,21,22,26,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1 |
| InChiKey | HKXBNHCUPKIYDM-CGMHZMFXSA-N |
| CID | 5281107 |
| Short Description | VDR agonist |
References
- JA Di Paolo et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 2011, 7(1), 41-50.
- Y Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J. Med. Chem. 2012, 55(10), 4539-4350.
- SL Tamn et al. Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives. Pharmacol. & Ther. 2013, 138(2), 294-309.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1676 | BXL 628 |
From $176.00 |
| 2516 | Tacalcitol |
From $181.50 |


